BiomX Inc. (NYSEAMERICAN:PHGE – Get Free Report) was the recipient of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 25,400 shares, a growth of 159.2% from the February 13th total of 9,800 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 89,200 shares, the short-interest ratio is currently 0.3 days.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of BiomX in a research note on Wednesday, January 8th.
View Our Latest Research Report on PHGE
BiomX Stock Performance
About BiomX
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
Featured Articles
- Five stocks we like better than BiomX
- Health Care Stocks Explained: Why You Might Want to Invest
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- The How and Why of Investing in Gold Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
